B.Riley Downgrades Ambrx Biopharma (AMAM) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts AMAM Hot Sheet
Price: $28.00 --0%
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
B.Riley analyst Yuan Zhi downgraded Ambrx Biopharma (NASDAQ: AMAM) from Buy to Neutral with a price target of $28.00 (from $26.00).
For an analyst ratings summary and ratings history on Ambrx Biopharma click here. For more ratings news on Ambrx Biopharma click here.
Shares of Ambrx Biopharma closed at $13.63 yesterday.
You May Also Be Interested In
- Evercore ISI Downgrades Reddit (RDDT) to In Line, Removes From Tactical Outperform List
- Digital Realty Trust (DLR) PT Lowered to $227 at Freedom Broker
- Stryker (SYK) PT Lowered to $325 at Piper Sandler
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
